IL13RA2 and neoplasm: It is noteworthy that CHI3L1 has the ability to bind to multiple receptors, such as the receptor for advanced glycation end products (RAGE), syndecan-1/αVβ3, interleukin 13 receptor alpha 2 (IL-13Rα2), and VEGFR2, and this binding leads to the activation of several signals related to inflammasome activation, neuronal inflammation, tumor metastasis and invasion, angiogenesis, apoptosis, carcinogenesis, Aβ accumulation, vascular smooth muscle cell activation, endothelial cell inflammation and atherogenesis (Fig. 2)28–30.